Example: Heart Attack

Clinical Trials on Coxsackievirus Infections

Total 57 results

NCT04690426

Recruiting

PROtocol for Coxsackievirus VaccinE in Healthy VoluNTteers

Conditions: Viral; Infection, Coxsackie(Virus)
NCT00438009

Completed

A Safety Study of Two Intratumoural Doses of Coxsackievirus Type A21 in Melanoma Patients (PSX-X03)

Conditions: Stage IV Melanoma
NCT03830073

Not yet recruiting

Assessment of the Different Etiological and Susceptibility Markers in Patients With Pancreatitis: Investigating IG4, Cytomegalovirus, Coxsackie- Virus, Genetic Polymorphism of Vitamin D Receptor Gene

Conditions: Acute Pancreatitis
NCT00235482

Completed

Intratumoural Administration of Coxsackievirus A21 for the Control of Malignant Melanoma (PXS-X02)

Conditions: Malignant Melanoma
NCT00636558

Completed

Coxsackie Virus A21 Administered Intravenously (IV) for Solid Tumour Cancers (PSX-X04)

Conditions: Melanoma; Breast Cancer; Prostate Cancer
NCT03737006

Active, not recruiting

Coxsackie Virus in Pregnancy and Congenital Heart Disease

Conditions: Congenital Heart Disease in Pregnancy
NCT02316171

Completed

CAVATAK (CVA21) in Non-muscle Invasive Bladder Cancer (VLA-012 CANON)

Conditions: Non-muscle Invasive Bladder Cancer
NCT00832559

Terminated

A Study of the Intratumoural Administration of CAVATAK to Head and Neck Cancer Patients (VLA-X06)

Conditions: Head and Neck Cancer
NCT02565992

Completed

Intratumoral CAVATAK (CVA21) and Pembrolizumab in Patients With Advanced Melanoma (VLA-011 CAPRA)

Conditions: Melanoma
NCT02307149

Completed

Intratumoral CAVATAK (CVA21) and Ipilimumab in Patients With Advanced Melanoma (VLA-013 MITCI)

Conditions: Melanoma
NCT03408587

Completed

CAVATAK® and Ipilimumab in Uveal Melanoma Metastatic to the Liver (VLA-024 CLEVER)

Conditions: Uveal Melanoma; Liver Metastases
NCT01227551

Completed

A Study of Intratumoral CAVATAK™ in Patients With Stage IIIc and Stage IV Malignant Melanoma (VLA-007 CALM )

Conditions: Malignant Melanoma
NCT01636882

Completed

CAVATAK in Patients With Stage IIIc or IV Malignant Melanoma to Extend Dosing to 48 Weeks (VLA-008 CALM Ext)

Conditions: Melanoma
NCT01302418

Completed

Collection and Testing of Respiratory Samples

Conditions: QIAGEN ResPlex II Advanced Panel; Influenza A; Respiratory Syncytial Virus Infections; Infection Due to Human Parainfluenza Virus 1; Parainfluenza Type 2; Parainfluenza Type 3; Parainfluenza Type 4; Human Metapneumovirus A/B; Rhinovirus; Coxsackie Virus/Echovirus; Adenovirus Types B/C/E; Coronavirus Subtypes 229E; Coronavirus Subtype NL63; Coronavirus Subtype OC43; Coronavirus Subtype HKU1; Human Bocavirus; Artus Influenza A/B RT-PCR Test; Influenza B
NCT01273246

Completed

Safety of an Inactivated Enterovirus Type 71 Vaccines in Healthy Children

Conditions: Hand-foot-mouth Disease; Infection; Viral, Enterovirus
NCT02066714

Completed

Neurodevelopment Outcomes Following Severe Hand Foot and Mouth Disease in Vietnam

Conditions: Hand Foot and Mouth Disease
NCT01313715

Completed

A Clinical Trial for Inactivated Vaccine (Vero Cell) Against EV71 in Chinese Children and Infants

Conditions: Hand, Foot, and Mouth Disease; Enterovirus Infections
NCT03281174

Completed

Five-year Immune Persistence Study of Inactivated Enterovirus Type 71 (EV71) Vaccine

Conditions: Hand, Foot and Mouth Disease
NCT01376479

Completed

Safety and Immunogenicity Study of an Inactivated Vaccine Against Hand, Foot and Mouth Disease Caused by Enterovirus 71

Conditions: Hand, Foot and Mouth Disease
NCT03266601

Completed

Effect of Recombinant Human Interferon α-2b Spray on Herpangina

Conditions: Herpangina
NCT04467541

Enrolling by invitation

Safety & Immunogenicity of Enterovirus Type 71 Vaccine in Healthy Adults and Children 6-71months

Conditions: Hand Foot & Mouth Disease
NCT01554930

Completed

Effectiveness and Safety of Chinese Medicine to Treat Hand, Foot, and Mouth Disease

Conditions: Hand, Foot, and Mouth Disease
NCT04637919

Not yet recruiting

Safety and Immunogenicity of High-dose IN-B001 in Healthy Subjects

Conditions: Hand, Foot and Mouth Disease
NCT04182932

Recruiting

Safety and Immunogenicity of CJ-40010 in Healthy Subjects

Conditions: Hand, Foot and Mouth Disease
NCT04111432

Recruiting

Safety and Immunogenicity of Concomitant Administration of EV71 Vaccine With Expanded Programme on Immunization Vaccines

Conditions: Hand, Foot and Mouth Disease